CTLA4 and neoplasm: Tumor-free mice that were initially treated with MP-OVA/Riboxxim alone or in combination with anti-CTLA-4 mAb were re-challenged on day 60 post tumor challenge with E.G7 tumor cells at the contralateral side of the primary tumor site.